(e)-3-(3,4-二甲氧基苯基)-2-丙烯酸甲酯 | 5396-64-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: (e)-3-(3,4-二甲氧基苯基)-2-丙烯酸甲酯
• 中文别名: 3,4-二甲氧基肉桂酸甲酯
• 英文名称: methyl 3,4-dimethoxycinnamate
• 英文别名: 3,4-dimethoxycinnamic acid methyl ester；Methyl 3-(3,4-dimethoxyphenyl)prop-2-enoate
• CAS: 5396-64-5
• 化学式: C₁₂H₁₄O₄
• mdl: MFCD00458425
• 分子量: 222.241
• InChiKey: JXRYDOZRPYFBKO-UHFFFAOYSA-N

物化性质

• 熔点：
  63-65?C
• 沸点：
  339.3±27.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮、氯仿、二氯甲烷、乙酸乙酯
• LogP：
  2.000 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090
• 储存条件：
  2-8℃

制备方法与用途

Methyl 3,4-dimethoxycinnamate不仅是黑孢子萌发的抑制剂，还能在Hep3B细胞中抑制整体DNA甲基化。

反应信息

• 作为反应物：
  描述：

  (e)-3-(3,4-二甲氧基苯基)-2-丙烯酸甲酯 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以81%的产率得到3,4-二甲氧基肉桂酸
  参考文献：
  名称：

  Bifunctional phenolic-choline conjugates as anti-oxidants and acetylcholinesterase inhibitors

  摘要：

  Because of the complex cascade of molecular events that can occur in the brain of an Alzheimer's disease (AD) patient, the therapy of this neurodegenerative disease seems more likely to be achieved by multifunctional drugs. Herein, a new series of dual-targeting ligands have been developed and in vitro bioevaluated. Their architecture is based on conjugating the acetylcholinesterase inhibition and anti-oxidant properties in one molecular entity. Specifically, a series of naturally occurring phenolic acids with recognized anti-oxidant properties (derivatives of caffeic acid, rosmarinic acid, and trolox) have been conjugated with choline to account for the recognition by acetylcholinesterase (AChE). The synthesized hybrid compounds evidenced AChE inhibitory capacity of micromolar range (rationalized by molecular modeling studies) and good antioxidant properties. Their effects on human neuroblastoma cells, previously treated with beta-amyloid peptides and 1-methyl-4-phenylpyridinium ion neurotoxins (to simulate AD and Parkinson's disease, respectively), also demonstrated a considerable capacity for protection against the cytotoxicity of these stressors.

  DOI：

  10.3109/14756366.2010.529806
• 作为产物：
  描述：

  异丁香酚甲醚 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.92h， 生成 (e)-3-(3,4-二甲氧基苯基)-2-丙烯酸甲酯
  参考文献：
  名称：

  Tandem allylic oxidation–condensation/esterification catalyzed by silica gel: an expeditious approach towards antimalarial diaryldienones and enones from natural methoxylated phenylpropenes

  摘要：

  开发了一种新的单锅法策略，利用丰富的甲氧基化苯丙烯类化合物，通过烯丙位氧化-缩合或烯丙位氧化-酯化序列，直接转化为相应的二烯酮（1,5-二芳基-2,4-戊二烯-1-酮）和烯酮（查耳酮和肉桂酸酯）。对上述合成的二芳基二烯酮和烯酮进行的初步抗疟活性研究表明，它们是开发新型经济抗疟药物的有希望的先导候选物。特别是，两个烯酮（12b和13b）的活性（IC50分别为4.0和3.4微摩尔）优于已知的天然抗疟化合物licochalcone（IC50=4.1微摩尔）。

  DOI：

  10.1039/c1ob05293d

文献信息

• [EN] SYNTHESIS OF OLIGOMERIC NEOLIGNANS AND THEIR USE<br/>[FR] SYNTHÈSE DE NÉOLIGNANES OLIGOMÈRES ET LEURS APPLICATIONS
  申请人：UNIV COLUMBIA

  公开号：WO2010074764A1

  公开（公告）日：2010-07-01

  Compounds having the structure formule (I) and their uses are described herein.

  具有结构式(I)的化合物及其用途在此描述。
• An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives
  作者：Paul LaBeaume、Ma Dong、Michail Sitkovsky、Elizabeth V. Jones、Rhiannon Thomas、Sara Sadler、Amy E. Kallmerten、Graham B. Jones

  DOI：10.1039/c003382k

  日期：——

  A one-pot route to 8-substituted xanthines has been developed from 5,6-diaminouracils and carboxaldehydes. Yields are good and the process applicable to a range of substrates including a family of A2A adenosine receptor antagonists. A new route to the KW-6002 family of antagonists is presented including a pro-drug variant, and application to related image contrast agents developed.

  已开发出一条从5,6-二氨基尿嘧啶和羰基化合物出发，制备8-取代黄嘌呤的一锅法路线。该方法产率高，适用于多种底物，包括一组A2A腺苷受体拮抗剂。本文介绍了一条制备KW-6002拮抗剂家族的新路线，包括一种前药变体，并应用于开发相关造影剂。
• Organocatalysis in the stereoselective bromohydrin reaction of alkenes
  作者：Sukanta Bar

  DOI：10.1139/v10-053

  日期：2010.7

  An efficient regio- and stereo-selective (>99:1) trans-bromohydrination (bromohydroxylation and bromomethoxylation) of alkenes including α,β-unsaturated carbonyl compounds with N-bromosuccinimide (NBS) has been achieved by using 1.0 mol% of N,N′-diarylthiourea catalyst.

  通过使用 1.0 mol%的 N,N′-二基硫脲催化剂，实现了烯烃（包括 α、β-不饱和羰基化合物）与 N-溴代琥珀酰亚胺（NBS）的高效区域和立体选择性（99:1）反式溴水化反应（溴羟化反应和溴甲氧基化反应）。
• Pd-Catalyzed desulfitative arylation of olefins by <i>N</i>-methoxysulfonamide
  作者：Subhadra Ojha、Niranjan Panda

  DOI：10.1039/d1ob02360h

  日期：——

  A novel Pd-catalyzed protocol for the desulfitative Heck-type reaction of N-methoxy aryl sulfonamides with alkenes was reported. The cross-coupling reaction was performed successfully with a variety of olefins to obtain aryl alkenes. Different substituents on the aromatic ring of N-methoxysulfonamides were also found to be compatible with the reaction conditions. Expectedly, the reaction proceeds through

  报道了一种用于N-甲氧基芳基磺酰胺与烯烃的脱硫 Heck 型反应的新型 Pd 催化方案。与多种烯烃成功地进行了交叉偶联反应，得到了芳基烯烃。N-甲氧基磺酰胺芳环上的不同取代基也被发现与反应条件相容。预期，该反应通过 CuCl 2促进氮自由基的产生和随后在热条件下脱磺酰化以提供用于 Pd 催化的偶联反应的芳基自由基进行。N-甲氧基磺酰胺被进一步开发用于在CuCl 2存在下合成对称联芳基化合物。
• [EN] OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] COMPOSÉS OXADIAZOLE, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011104680A1

  公开（公告）日：2011-09-01

  The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及氧代唑化合物的所有立体异构体和互变异构体形式以及它们在所有比例的混合物中；以及它们的药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的前药和药学上可接受的多形态。该发明还涉及制备氧代唑化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物可用于治疗癌症，特别是慢性髓样白血病（CML）。本发明还提供了一种治疗癌症的方法，即通过向需要的哺乳动物投予所述化合物或其药物组合物的治疗有效剂量。